Primary analysis of a randomized phase II, multicenter trial: Neoadjuvant weekly nab-paclitaxel 100mg/m2 followed by FE100C compared with docetaxel 75mg/m2 followed by FE100C for early breast cancer in Japan.

被引：0
|
作者：
Kuwayama, Takashi
Yamauchi, Hideko
Takano, Toshimi
Tsugawa, Koichiro
Sato, Takanobu
Kitani, Akira
Hayashi, Naoki
Okuyama, Hiromi
Nakamura, Seigo
机构：
[1] Showa Univ, Sch Med, Dept Surg, Div Breast Surg Oncol, Tokyo 142, Japan
[2] St Lukes Int Hosp, Tokyo, Japan
[3] Toranomon Gen Hosp, Tokyo, Japan
[4] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan
[5] Tokyo Med & Dent Univ, Dept Breast Surg Oncol, Meguro Ku, 2-3-8 Nakameguro, Tokyo, Japan
[6] Showa Univ Med, Dept Breast Surg Oncol, Tokyo, Japan
[7] Showa Univ, Sch Med, Tokyo 142, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期
关键词：
D O I：
10.1200/jco.2015.33.28_suppl.136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
136
引用
收藏
页数：1
相关论文
共 12 条
  • [1] A Phase I Trial of 100mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer
    Tamura, Tomoki
    Hirata, Taizo
    Tabata, Masahiro
    Hinotsu, Shiro
    Hamada, Akinobu
    Motoki, Takayuki
    Iwamoto, Takayuki
    Mizoo, Taeko
    Nogami, Tomohiro
    Shien, Tadahiko
    Taira, Naruto
    Matsuoka, Junji
    Doihara, Hiroyoshi
    ACTA MEDICA OKAYAMA, 2016, 70 (05) : 425 - 427
  • [2] Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
    Furlanetto, Jenny
    Jackisch, Christian
    Untch, Michael
    Schneeweiss, Andreas
    Schmatloch, Sabine
    Aktas, Bahriye
    Denkert, Carsten
    Wiebringhaus, Hermann
    Kuemmel, Sherko
    Warm, Mathias
    Paepke, Stefan
    Just, Marianne
    Hanusch, Claus
    Hackmann, John
    Blohmer, Jens Uwe
    Clemens, Michael
    Costa, Serban Dan
    Gerber, Bernd
    Nekljudova, Valentina
    Loibl, Sibylle
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 495 - 506
  • [3] Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
    Jenny Furlanetto
    Christian Jackisch
    Michael Untch
    Andreas Schneeweiss
    Sabine Schmatloch
    Bahriye Aktas
    Carsten Denkert
    Hermann Wiebringhaus
    Sherko Kümmel
    Mathias Warm
    Stefan Paepke
    Marianne Just
    Claus Hanusch
    John Hackmann
    Jens Uwe Blohmer
    Michael Clemens
    Serban Dan Costa
    Bernd Gerber
    Valentina Nekljudova
    Sibylle Loibl
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2017, 163 : 495 - 506
  • [4] Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2- Early-stage Breast Cancer
    Kuwayama, Takashi
    Nakamura, Seigo
    Hayashi, Naoki
    Takano, Toshimi
    Tsugawa, Koichiro
    Sato, Takanobu
    Kitani, Akira
    Okuyama, Hiromi
    Yamauchi, Hideko
    CLINICAL BREAST CANCER, 2018, 18 (06) : 474 - 480
  • [5] Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial
    Bono, P.
    Kellokumpu-Lehtinen, P. -L.
    Alanko, T.
    Kokko, R.
    Asola, R.
    Turpeenniemi-Hujanen, T.
    Jyrkkio, S.
    Kataja, V.
    Leinonen, M.
    Joensuu, H.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 595 - 596
  • [6] Phase III study of docetaxel 100 versus 75 versus 60 mg/m2 as second line chemotherapy in advanced breast cancer.
    Mouridsen, H
    Harvey, V
    Semiglazov, V
    Voznyi, E
    Robinson, B
    Murawsky, M
    Haregewoin, A
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S88 - S88
  • [7] Feasibility study of weekly nanoparticle albumin-bound (nab)-paclitaxel (150 mg/m2) followed by 5FU, epirubicin, plus cyclophosphamide (FEC) as neoadjuvant chemotherapy for HER2-negative breast cancer
    Tsugawa, K.
    Kawamoto, H.
    Kojima, Y.
    Tsuchiya, K.
    Shimo, A.
    Hayami, R.
    Nishikawa, T.
    Yabuki, Y.
    Kanemaki, Y.
    Maeda, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S51 - S51
  • [8] A phase II trial of taxotere (TXT) 100 or 75 mg/m2 as 2nd line chemotherapy (CT) in patients (PTS) with metastatic breast cancer (mbc) with stratification according to prognosis factors
    Malik, I
    Roth, A
    Ghilezan, N
    Cufer, T
    Lazarev, A
    Doval, D
    Ionescu-Goga, S
    Chemozemsky, I
    Quinaux, E
    Chirina, N
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S320 - S320
  • [9] Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer
    Quoix, E
    Lebeau, B
    Depierre, A
    Ducolone, A
    Moro-Sibilot, D
    Milleron, B
    Breton, JL
    Lemarie, E
    Pujol, JL
    Brechot, JM
    Zalcman, G
    Debieuvre, D
    Vaylet, F
    Vergnenegre, A
    Clouet, P
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 38 - 44
  • [10] Docetaxel:: Standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy -: A phase II single-center study
    Salminen, E
    Bergman, M
    Huhtala, S
    Ekholm, E
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1127 - 1131
12